Endovenous Laser Ablation Clinical Trial
Official title:
Comparison of Two Different Safety Distances to Sapheno-femoral Junction for EndoVenous Laser Ablation Treatment of Great Saphenous Vein Incompetence: a Prospective Randomized Double-blind Study
Chronic venous disease is one of the most common diseases in the western world and worldwide
with a prevalence of 83,6%. It is a chronic progressive disease, which causes a significant
burden on health systems, treatment and care of these patients. Recurrence of varicose veins
after successful treatment remains a problem and has been reported in up to 30% of patients
after endovenous laser ablation (EVLA), which is the recommended treatment of choice for
incompetence of the truncal veins. The aim of this project is to investigate a variation of
the EVLA, which has the potential to reduce the recurrence rate in the long-term. If this
assumption is true, the investigators expect reduction of costs in the health system and
improved quality of life for individual patients.The primary objective of the project is the
evaluation of long-term anatomical effectiveness of EVLA treatment with and without keeping a
distance to sapheno-femoral junction (SFJ), defined as complete obliteration of the great
saphenous vein (GSV) or absence of an open saphenous stump at the SFJ after 3 years.
Secondary objectives are:
1. . Evaluation of the effectiveness of EVLA treatment with and without keeping a distance
to SFJ, measured as duplex sonographic reflux (≥ 0,5 sec) in the GSV or any other axial
vein at the SFJ after 1 year and 3 years.
2. . Evaluation of the anatomical effectiveness of EVLA treatment with and without keeping
a distance to SFJ, measured as the length of the open saphenous stump (in centimeters)
after 1 year and 3 years.
3. . Assessment of quality of life 3 months, 1 year and 3 years after EVLA.
4. . Evaluation of the clinical efficacy and tolerability measured as a clinical score at 3
months, 1 year and 3 years after EVLA.
5. . Safety assessment measured as the number of thromboembolic events 1 week and 3 months
after EVLA.This project is planned as a prospective randomized parallel group
double-blind study.
For the assessment of efficacy and safety parameters, clinical examinations and duplex
sonographic examinations will be performed 3 months, 1 year and 3 years after the
intervention.
For the assessment of tolerability endpoints, clinical scores and quality of life score will
be performed 3 months, 1 year and 3 years after EVLA. Clinical scores include Clinical,
Etiologic, Anatomical, and Pathophysiological Classification (CEAP) and Venous Clinical
Severity Scoring (VCSS) and for evaluation of quality of life Aberdeen Varicose Veins
Questionnaire (AVVQ) will be used.
Introduction and background information Chronic venous disease is one of the most common
diseases in the western world and worldwide with a prevalence of 83,6%. It is a chronic
progressive disease, which causes a significant burden on health systems, treatment and care
of these patients.
There are different methods for treatment of insufficiency of the GSV, which have good
evidence: open surgery and minimally invasive techniques including ultrasound-guided foam
sclerotherapy (UGFS), radiofrequency ablation (RFA) and endovenous laser ablation (EVLA).
UGFS and thermal ablation techniques such as EVLA have become widely used alternatives to
surgery for the treatment of venous reflux. The safety and efficacy of EVLA has been
demonstrated in several studies. According to guidelines of the European Venous Forum (EVF),
the International Union of Angiology (IUA) and the European Society for Vascular Surgery
(ESVS) the treatment of GSV reflux with EVLA is recommended in preference to surgery, Grade
of Recommendation 1A.
Rationale of the project Recurrence of varicose veins after successful treatment remains a
problem and has been reported in up to 30% of patients after EVLA. Treatment with EVLA aims
at complete obliteration of the vein in the treated area. According to the literature a
safety distance of 1-2 cm from the sapheno-femoral junction (SFJ) is obligatory in all
patients undergoing EVLA of the GSV. In earlier trials laser systems equipped with a bare
fibre were used, which emit shorter wavelength of 810 nm antegrade with an absorption maximum
in the range of haemoglobin. A new generation of laser devices with a wavelength of 1470 nm
has been introduced in recent years. The absorption coefficient of water at 1470 nm is
significantly higher than in the wavelength range of 810 ‒ 1064 nm, which results in a much
better control of the laser energy applied. The patented radial (360°) fibre ensures radial
delivery of energy inducing homogenous photothermal destruction of the vein wall. By avoiding
perforation of the vein wall and associated thermal irritation of the surrounding tissue,
post-operative pain is minimized, as are ecchymosis and other side effects noticed with the
previously used bare fibres.
In prospective studies it has been demonstrated that EVLA of the GSV using radial fibres has
fewer side effects compared to EVLA of the GSV using bare fibre. It is not known whether the
use of radial fibres results in a complete vascular closure of GSV up to the SFJ, and whether
a remaining non-occluded vessel stump could be a cause of recurrence. Applying EVLA without
keeping a distance of 1-2 cm to the SFJ is used with increasing frequency by many
specialists, but there is no controlled data about this topic.
At our department the investigators use a 1470 nm laser with radial fibres without keeping a
distance to SFJ and have no complications observed so far.
The aim of this project is to compare the efficacy and safety parameters when two different
distances from the SFJ during EVLA of the GSV are kept. Our scientific hypothesis is that
EVLA of the GSV with placing the catheter tip at the SFJ without keeping a distance to the
SFJ leads to better anatomical results (complete obliteration of the GSV) after three years
compared to EVLA with keeping a distance of 2 cm from the SFJ. If this hypothesis is true, a
reduction in the incidence of recurrent varicose veins after EVLA of the GSV would be
expected when placing the catheter tip without keeping a distance to the SFJ. This risk
reduction would have a positive impact on patient quality of life and on the consumption of
resources in the health system.
Objectives of the project (hypothesis)
Primary objective:
The primary objective of the study is the complete anatomical obliteration rate of the
ablated GSV or absence of an open saphenous stump 3 years after EVLA in both groups.
Null hypothesis: EVLA without keeping a distance to the SFJ does not result in an equal
obliteration rate of the GSV or absence of an open saphenous stump 3 years after surgery
compared to EVLA with maintaining a distance to the SFJ of 2 cm.
Alternative hypothesis: EVLA without keeping a distance to the SFJ results in an equal
obliteration rate of the GSV or absence of an open saphenous stump 3 years after surgery
compared to EVLA with maintaining a distance from the SFJ of 2 cm.
Secondary objectives are:
Complete obliteration rate of the GSV or absence of an open saphenous stump 1 year after EVLA
in both groups Duplex sonographic reflux (≥0,5 sec) in the GSV or any other axial vein at the
SFJ 1 and 3 years after EVLA Length of the open saphenous stump (in centimetres) 1 year and 3
years after EVLA Clinical efficacy and tolerability measured as a clinical score 3 months, 1
year and 3 years after EVLA Overall quality of life 3 months, 1 year and 3 years after EVLA
Overall safety measured as the number of thromboembolic events 1 week and 3 months after EVLA
Design of the clinical investigation Prospective, randomized, parallel group, double blind
study Population Subject population: Patients with incompetence of the GSV that have been
referred to the phlebologic-angiological unit of the Division of General Dermatology and
Dermato-Oncology, Medical University of Vienna Methodology Measurements and analysis
Eligibility and Enrolment Study team will ensure that patients meet the criteria for study
enrolment. Patients must consent to screening for eligibility. Enrolment will occur after
eligibility is established and informed consent is provided.
Screening In all patients, past history will be collected including drug history. There will
be a physical examination including height- and body weight measurements. All patients will
be examined clinically and by duplex sonography prior to EVLA. Inclusion and exclusion
criteria will be checked.
Clinical examination Clinical, etiologic, anatomic, pathophysiology (CEAP) classification
will be performed at screening and by a blinded investigator at the baseline examination, as
well as during the follow-up period at 3 months, 1 and 3 years. The Venous Clinical Severity
Score (VCSS) will be also determined at screening and by a blinded investigator at baseline,
3 months, 1 year and 3 years post procedure.
A blinded investigator will clinically examine all patients 1 week postoperatively, 3 months,
1 year and 3 years after EVLA.
Quality of life All patients, who are eligible to enter the study, will fill in a
questionnaire for quality of life.
The quality of life will be determined by means of Aberdeen Varicose Vein Questionnaire
(AVVQ) at baseline and 3 months, 1 year and 3 years after EVLA. The questions will be
answered by the patient and documented by a blinded investigator at baseline and after 3
months, 1 year and 3 years; see Table 1.
Duplex sonographic examination Duplex scanning investigation (LOGIQ® 7 General Electric
Austria GmbH) will be performed at screening to establish the diagnosis of incompetence of
the GSV and to check the inclusion and exclusion criteria for eligibility. Follow-up
investigation will be performed 1 week postoperatively, 3 months, 1 year and 3 years after
EVLA. During the trial a blinded investigator without knowledge of the patient group will
perform the duplex ultrasound examination. If a diagnosis of EHIT or venous thromboembolic
events (VTE) is made, weekly duplex sonographic controls will be performed until resolving of
EHIT.
EVLA will be performed in local tumescent anaesthesia or general anaesthesia depending on the
patient's preference and clinical findings. Treatment will be performed on an inpatient
basis.
This procedure will be performed with the patient and all people in the room wearing
protective eye goggles to guard against unplanned exposure to the laser.
The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470
nm/15W, Biolitec). The GSV will be punctured with an 18-gauge needle under sonographic
guidance and the laser fibre will be introduced by Seldinger technique at the distal point of
insufficiency, possibly no deeper than the proximal tibia. The laser catheter will be
advanced forward to the SFJ. The exact position of the catheter tip will be fixed under
ultrasound guidance depending on randomization, either without keeping a distance to the SFJ
or 2 cm below the SFJ. Thereafter, the saphenous vein will be overmolded with tumescence (in
patients with tumescent anaesthesia) or saline (in patients with general anaesthesia) also
under ultrasound guidance. The laser energy will be administered under continuous pull back
of the catheter in a total dose of 80J /cm2 and 10W/cm2. EVLA will be applied only for the
GSV. In the same session insufficient side branches will be removed by phlebectomy.
Both the patient and the investigator will be blinded with respect to the treatment group.
After EVLA compression stockings class 2 (25-35 mm Hg) will be applied for a week during day
and night. Patients will be advised to wear tight length compression stockings class 2 for
another 3 weeks daytime if additional phlebectomias have been performed. The patient should
move around a lot and drink enough, at least 2 litres per day. Heat procedures such as hot
baths, thermal baths, sauna, solarium, and direct exposure to sunlight should be avoided for
the duration of 4-6 weeks after the procedure. Short shower with lukewarm water is allowed.
Analgetics and NSAIDs upon need are postoperatively allowed. In patients at thrombotic risk
Low Molecular Weight Heparin (LMWH) in prophylactic dose will be administered for at least 1
week and for a maximum of 6 weeks after EVLA depending on individual risk. The following
patients are classified as risk patients: patients with chronic inflammatory diseases,
patients with cancer, patients with previous thromboembolic events, thrombophilia patients,
patients with obesity, patients on estrogen-containing oral contraceptives or hormone
replacement therapy and immobilization postoperatively for different reasons.
Follow-up Follow-up investigations will be carried out 1 week, 3 months, 1 year and 3 years
after EVLA. If a diagnosis of EHIT or VTE is made, weekly duplex sonographic controls will be
performed until resolving of EHIT.
All patients will undergo physical and duplex sonographic examination 1 week postoperatively.
All adverse events and complaints of the patients will be documented in the CRF at every
follow-up visit. At 3 months follow up every patient will be examined clinically with
determination of CEAP and VCSS and duplex sonographic as described above, methodology, duplex
sonographic examination. The Quality of life will be determined by means AVVQ and clinical
photographs will be taken. These investigations will be repeated 1 year and 3 years after
EVLA.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05001776 -
Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous Vein
|
Phase 4 | |
| Completed |
NCT02017106 -
Concomitant or Sequential Phlebectomy After Endovenous Laser Therapy for Varicose Veins
|
N/A |